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Abstract
Curcumin, a natural compound and ingredient in curry, has antiinflammatory, antioxidant, and anticarcinogenic properties.
Previously, we reported that curcumin abrogated influenza virus infectivity by inhibiting hemagglutination (HA) activity.
This study demonstrates a novel mechanism by which curcumin inhibits the infectivity of enveloped viruses. In all analyzed
enveloped viruses, including the influenza virus, curcumin inhibited plaque formation. In contrast, the nonenveloped
enterovirus 71 remained unaffected by curcumin treatment. We evaluated the effects of curcumin on the membrane
structure using fluorescent dye (sulforhodamine B; SRB)-containing liposomes that mimic the viral envelope. Curcumin
treatment induced the leakage of SRB from these liposomes and the addition of the influenza virus reduced the leakage,
indicating that curcumin disrupts the integrity of the membranes of viral envelopes and of liposomes. When testing
liposomes of various diameters, we detected higher levels of SRB leakage from the smaller-sized liposomes than from the
larger liposomes. Interestingly, the curcumin concentration required to reduce plaque formation was lower for the influenza
virus (approximately 100 nm in diameter) than for the pseudorabies virus (approximately 180 nm) and the vaccinia virus
(roughly 3356 2006 200 nm). These data provide insights on the molecular antiviral mechanisms of curcumin and its
potential use as an antiviral agent for enveloped viruses.
Citation: Chen T-Y, Chen D-Y, Wen H-W, Ou J-L, Chiou S-S, et al. (2013) Inhibition of Enveloped Viruses Infectivity by Curcumin. PLoS ONE 8(5): e62482.
doi:10.1371/journal.pone.0062482
Editor: David Harrich, Queensland Institute of Medical Research, Australia
Received November 16, 2012; Accepted March 22, 2013; Published May 1, 2013
Copyright:  2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from National Science Council (98-2313-B-005-015-MY3, 101-2321-B-005-005) and National Chung-Hsing University
(TCVGH-NCHU1017612). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wlhsu@dragon.nchu.edu.tw
¤ Current address: Department of Microbiology & Immunology, University of Otago, Otago, New Zealand
. These authors contributed equally to this work.
Introduction
Curcumin (diferuloylmethane), a natural compound derived
from turmeric (Curcuma Longa) is a widely used spice and coloring
agent in food [1]. Accumulating evidence suggests that curcumin
displays a number of pharmacological activities, including
antiinflammatory [2], antioxidant [3] and antitumor [4,5]
activities. Recent studies have also shown that curcumin has
antiviral activity [6,7,8,9,10]. In the study by Mazumder et al.,
curcumin inhibited HIV replication [11]. The specific interaction
of curcumin with the viral proteins integrase and protease, which
play central roles in viral replication, might represent the
underlying mechanism for this effect [12]. Kutluay et al. also
reported that curcumin treatment inhibited herpes simplex virus
(HSV) immediate-early gene expression, possibly by interfering
with the recruitment of RNA polymerase II to immediate-early
gene promoters [13]. In other previous studies, curcumin inhibited
several intracellular signaling pathways, including the Mitogen-
activated protein kinase (MAPKs), phosphoinositide 3-kinase/
protein kinase B (PI3K/PKB), and nuclear factor kappa B (NF-kB)
pathways [14,15,16], and dysregulated the ubiquitin proteasome
system (UPS) [17]. Activation of the NF-kB pathway is involved in
the efficient replication of hepatitis C (HCV) [18] and influenza
[19] viruses. Mazur et al., reported that treatment of influenza
infection with NF-kB inhibitors downregulated influenza virus
replication significantly [20]. However, Kim et al. described that
curcumin inhibits HCV replication by suppressing the activation
of Akt-SREBP-1, not through the NF-kB pathway [21]. In a recent
study, curcumin decreased coxsackievirus B3 (CVB3) infection by
dysregulating the UPS, a system required for CVB3 replication
[6]. Overall, the finding from other research groups suggested that
curcumin exerts antiviral activity through different mechanisms in
different viruses; these mechanisms involve a direct inhibition of
viral replication machinery or suppression of a cellular signaling
pathway essential for viral replication.
In our previous study, treatment of cells with curcumin prior to
infection markedly reduced the influenza A virus (IAV) yield at
subcytotoxic doses [10]. This suggested that one of curcumin’s
effects are mediated through the suppression of cellular signaling,
possibly the NF-kB pathway. More strikingly, adding curcumin to
the cell medium during viral adsorption inhibited virus pro-
duction, and influenza virus exposed to curcumin before infecting
MDCK cells markedly inhibited plaque formation [10]. By means
of hemagglutination inhibition (HI) assays further demonstrated
that curcumin interferes with HA receptor binding activity.
Collectively, these assays implicated that curcumin might directly
or indirectly interact with viral particles to interrupt early stage of
IAV infection.
It was shown that curcumin influences a wide range of
membrane proteins, by modulating the properties of the host
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lipid bilayer [22,23]. As the HA protein is expressed on the
envelope of the influenza virus, it is worthwhile to explore whether
curcumin’s inhibitory effect is only on the HA activity of the
influenza virus or it is deleterious to membrane proteins of other
viruses. In this work, the effects of curcumin on the infectivity of
several viruses were investigated and their potential underlying
mechanisms were also discussed.
Materials and Methods
Cell Culture and Virus Infection
Madin-Darby canine kidney (MDCK; CCL-34) cells and
African green monkey kidney cells BSC-1 (CCL-26), bought from
American Type Culture Collection (ATCC), and Vero cells
(ATCC CCL-81), a gift from Dr. S.S. Chiou, Graduate Institute of
Microbiology and Public Health, Natinoal Chung-Hsing Univer-
sity (NCHU), were cultured in minimal-essential medium (MEM)
with 10% heat-inactivated fetal bovine serum (FBS), penicillin
100 U/ml, and streptomycin 10 mg/ml. Porcine kidney (PK-15;
BCRC 60057) cells, originally obtained from Bioresource Collec-
tion and Research Center (BCRC) of the Food Industry Research
and Development Institute of Taiwan, were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM, Hyclone) supple-
mented with penicillin 100 U/ml, streptomycin 10 mg/ml, and
5% of heat-inactivated FBS. Before infection, cells were washed
with PBS and cultured in medium supplemented with antibiotics
but without FBS (addition of 1 mg/ml of Worthington trypsin for
influenza virus).
Human influenza virus PR8, A/Puerto Rico/8/34 (H1N1), was
amplified in MDCK cells. Viruses for haemagglutination in-
hibition (HI) test were amplified in 10-day-old embryonated
chicken eggs at 37uC for 2 days. The allantoic fluid was harvested
and the titer of viruses was determined by standard plaque
formation assay or hemagglutination (HA) test. Vaccinia virus,
kindly provided by Dr. L Tiley in Department of Veterinary
Medicine, Cambridge, UK, was grown in BSC-1 cells. Enterovirus
71 viruses (EV71), a gift from Dr. C. W. Lin, Department of
Medical Laboratory Science and Biotechnology, China Medical
University, were amplified in Vero cells. Pseudorabies viruses
(PRV), obtained from Dr. T.J. Chang, were cultured in PK-15
cells. Japanese encephalitis virus (JEV) and Dengue virus type II
(DVII), provided by Dr. S. S. Chiou, Graduate Institute of
Microbiology and Public Health, NCHU, were cultured in Vero
cells. Newcastle Disease viruses (NDV) for HA inhibition test were
kindly provided by Dr. J. H. Shien, in Department of Veterinary
Medicine, NCHU.
Chemicals
Curcumin, obtained from Sigma-Aldrich, were dissolved in
dimethyl sulfoxide (DMSO) at a stock concentration of 100 mM
and stored in 280uC and were freshly diluted with infection
medium prior to experiment.
Cytotoxicity Test
Curcumin, 100 mM dissolved in dimethyl sulfoxide (DMSO),
were freshly diluted with medium prior to experiment. 1.56105 of
cells grown in 24-well plates for 24 hours were washed with PBS
and were treated with serially diluted curcumin or DMSO at
37uC, 5% CO2 for 24 hours. Amplification of cells was measured
directly by the total cell counts and the survival rate was estimated
by the ratio of living cells/total cell counts by staining of 0.4%
trypan blue. The cytotoxicity was estimated by comparison of the
cell survival rate of curcumin-treated cells with that of DMSO-
treated. The mock- treatment control was arbitrary set as 100%.
Plaque Assay
MDCK cells grown to 80% confluence were washed twice with
PBS followed by infection with serial dilutions of supernatants
containing virus progenies in infectious medium i.e. MEM
supplemented with 1 mg/ml of trypsin (Worthington, Freehold,
NJ, USA) and antibiotics. After 2 hours absorption at 37uC,
unbound viruses inoculums were removed and cells were then
cultured with 1 ml/well MEM supplemented with 0.6% agarose
at 37uC, 5% CO2 for 2 days. Viral plaques were visualized by
staining with Giemsa (Sigma).
Time-of-drug Addition Test on JEV and Dengue Virus
Infection
Ten microliter of Curcumin (or DMSO, the solvent control) or
were added to the medium at various times of JEV infection
(200 pfu). Briefly, (1) full-time treatment: curcumin was included
in the cell culture medium for 8 h and throughout the time of
infection; (2) co-treatment: curcumin mixed with JEV in the
infection medium was simultaneously added onto the cells and left
on the cells throughout; (3) post-infection: curcumin was added to
cells at 2 hours post infection and remained throughout the time of
infection. After virus adhesion, virus inoculums were removed and
vero cells were cultured in MEM (without FBS) containing 1%
methylcellulose. The infectivity was measure according to the
plaque formation units.
Plaque Reduction Assay
To estimate the infectivity of viruses after curcumin treatment,
2000 pfu of PR8, vaccinia virus, EV71, JEV, DVII, or PRV
particles were pre-incubated with 30 mM (unless otherwise stated)
of curcumin at room temperature for one hour. Remaining
infectivity after curcumin treatment was determined by plaque
assay. To be able to measure the plaque formation number, the
curcumin-treated viruses mix was further diluted to 1021, 1022,
1023 with medium without FBS and added to appropriate cell
lines. After 1 hour absorption at 37uC, the virus inoculums were
removed and cells were then cultured with 1 ml/well MEM
supplemented with 0.6% agarose for influenza (or medium
containing 1% methylcellulose for other viruses) at 37uC, 5%
CO2 for 2 days or until the plaque was visible. Viral plaques were
fixed by methanol and stained with crystal violet (Sigma).
Hemagglutination Inhibition (HI) Test
The hemagglutination (HA) titer of virus stock were initially
determined by standard HA assay and 4 HA units (HAU) of
viruses were then used for HI test. Briefly, curcumin stocks were
diluted in PBS to a concentration of 1 mM (the highest
concentration in the assay), and serial dilutions of curcumin were
prepared by addition of 25 ml curcumin (1 mM) into the well of
round-bottomed 96-well micro-plates, followed by 2-fold serial
dilutions with PBS for 7 times. Twenty-five ml of virus stock were
added into each well and incubated at room temperature for 1
hour. Subsequently, 50 ml of 0.75% chicken erythrocyte stocks
were added to each well. The hemagglutination reaction was
observed after 30 min incubation.
Transfection Test
Cells were seeded into 24-well plates and grown to 90%
confluence. The 4 ml of Cellfectin (Invitrogen, Carlsbad, CA,
USA) and 0.8 mg of pEGFP-C1 plasmid (Clontech) were each
diluted with 100 ml of Opti-MEM (Invitrogen, Carlsbad, CA,
USA). Both of the diluted components were mixed and incubated
at room temperature for 20 min. Subsequently, 30 mM or DMSO
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was added to the transfection reagent/DNA mixture and kept at
room temperature for 40 min before added to the cell monolayer.
The transfection efficiency and the intensity of GFP in each cell
were recorded by flow cytometry analysis and fluorescent
microscopy at 24-hour post transfection.
Flow Cytometry Analysis
Transfected cells were washed with PBS and harvested in 1 mL
of PBS. The signal of eGFP was then analyzed at least 10000 cells
using FL-1 filter by FACS Calibur flow cytometer (BD
Biosciences, MA, USA).
Preparation of Liposome
The fluorescent SRB dye-loaded liposomes were prepared by
a hydration/freezing and thawing/extrusion method [24]. The
mixture of DPPC, DPPG, and cholesterol in a molar ratio of
45:5:50 was dissolved in a solution of 6 ml chloroform, 1 ml
methanol, and dried in a rotary evaporator. The dried lipid film
was hydrated by the addition of 3 ml of 0.15 M SRB solution (in
0.02 M HEPES, pH 7.5, osmolality 530 mmol/kg). The lipid
solution was processed with 5 freeze and thaw cycles, and then
dependent on the final size of the liposomes desired, the liposomes
were sequentially extruded by passing through a mini high-
pressure extruder (Avanti Polar Lipids, Inc., AL, USA) with
different pore-sizes (400, 200, and then 100 mm) of polycarbonate
membrane (Whatman, NJ, USA). Unencapsulated SRB was
removed by gel filtration using a Sephadex G-50 column with
Tris-buffered saline (TBS: 0.02 M Tris with 0.15 M NaCl, 0.01%
NaN3, pH 7.5) containing sucrose (osmolality 530 mmol/kg).
Finally, the size of the liposomes was confirmed by a dynamic
light-scattering measurement using a nanosizer 90ZS (Malvern
Instruments, Worcestershire, UK).
Treatment of Liposome with Curcumin
Liposome diluted in TBS (50 mM Tris base and 150 mM
NaCl, osmolality 530 mmol/kg) was incubated with various
concentrations of curcumin, DMSO (negative control), or
15 mM n-octylglucoside (n-OG), a detergent serving as positive
control, at room temperature for one hour. The leakage of
Sulforhodamine B (SRB) fluorescence was detected by Spectra-
Max M2e Microplate Reader (Molecular Devices, Inc., California,
United States) at excitation wavelength of 490 nm.
To test whether influenza virus can reverse the curcumin’s effect
on liposome, we added 2 different doses of influenza virus particles
(2000 PFU and 10 000 PFU) to curcumin and SRB-loaded
liposomes, and then detected fluorescence after 1 h incubation.
Time Course Assay of Curcumin Pre-treatment
PR8 virus particles (2000 pfu) were mixed with 30 mM of
curcumin in 200 ml. At 0, 5, 10, 20, 40, 60 min after curcumin
treatment, an aliquot of 5 ml was added to MDCK cells in a well
containing 495 ml infectious medium to make the curcumin
concentration below viral inhibitory effect (i.e. 0.3 mM). The
infectivity of PR8 was determined by the standard plaque assay to
determine the infectivity of influenza virus.
Characterization of Curcumin Effect on Plaque Formation
Ability
PR8 virus particles (2000 pfu) were pre-incubated with 30 mM
(unless otherwise stated) of curcumin at room temperature for one
hour. Subsequently, the curcumin-virus mixture was diluted with
fresh infectious medium to the concentration of 6 mM, 3 mM,
1.5 mM and kept at room temperature for one hour followed by
the standard plaque assay.
Replication of Curcumin-treated Viruses in Embryonated
Eggs
The experiment protocol was approved by the Committee on
the Ethics of Animal Experiments of National Chung Hsing
University (Approval No: 97-91). The Embryonated hen’s eggs
were purchased from the Livestock Research Institute, Chunan,
Taiwan and incubated in hatchery until 10-day-old. Fifty or
5000 pfu of PR8 viruses were incubated with 30 mM of curcumin
in a total volume of 500 ml infectious medium. One hour after
incubation, inoculums were injected into the allantoic sac of
embryonated hen’s eggs. Treated eggs were incubated in 37uC
incubator for 18 or 24 hours, the yield of virus progeny was
determined by HA test.
Statistical Analysis
All data were calculated by Microsoft Excel. Results from at
least three independent experiments were reported as mean values
6 mean of standard deviations (S.E.M.).
Results
Curcumin blocked HA Activity of Newcastle Disease Virus
(NDV)
In our previous study, curcumin treatment abrogated the HA
activity of the IAV subtypes H1N1 and H6N1 [10]. In this study,
we treated paramyxovirus NDV, another virus that displays HA
activity, with curcumin to determine if its effect is specific to the
influenza virus. We incubated 4 HA units of NDV with various
concentrations of curcumin for 60 min at room temperature and
then assessed red blood cell (RBC) agglutination. Results showed
that curcumin pretreatment (at concentrations of 31.2 mM or
higher) inhibited the binding of NDV to chicken RBCs, as
indicated by the spot-like appearance of non-hemagglutinated cells
(Fig. 1A).
Curcumin Inhibits Plaque Formation in Enveloped Viruses
It was indicated that curcumin modifies the lipid bilayer and
influences membrane protein function [22]. The viral envelope is
membranous structure; therefore, a time-of-drug addition test was
employed to determine whether curcumin can also inhibit other
enveloped viruses. Accordingly to the cytotoxicity test, 30 mM of
curcumin slightly inhibit the growth of vero cells (Fig. S1), and
therefore 10 mM curcumin was used for this assay. As indicated in
Fig. 1B, including of curcumin throughout the time of infection
(i.e. full-time treatment) completely abrogated the infectivity of two
flaviviruses, JEV and Dengue (type 2; DV-II). Noticeably, addition
of curcumin upon the viral attachment (i.e. co-treatment) pro-
nouncedly inhibited both JEV and DV-II plaque formation; to
a similar extent of full-time treatment. In contrast, no effect was
observed, when curcumin was added after viral entry. These
findings are consistent with the effect on influenza virus that
curcumin blocks the virus infectivity by direct or indirect
interfering the function of envelope protein. Since HA activity of
NDV was also inhibited by curcumin, we then wonder whether
curcumin generally affects the infectivity of enveloped viruses.
Since IAV, NDV and flavivirus analyzed in this assay were all
RNA viruses, one enveloped DNA virus, pseudorabies virus (PRV
swine herpes virus) was then used to test the possibility. The effect
of curcumin on the infectivity of enveloped viruses was evaluated
by the plaque formation assay. As shown in Fig. 2A, as with that of
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JEV, and DV-II viruses, pretreatment of PRV, with 30 mM of
curcumin strongly inhibited plaque formation.
To determine whether the effects on the infectivity is specific to
viruses with envelop, a nonenveloped virus, enterovirus 71 (EV71)
was then included in the same set of test. For comparative analysis,
2000 PFU of EV71, influenza virus and JEV were incubated with
different concentrations of curcumin and viral viability was
evaluated using plaque assay. In contrast to the observations in
the IAV and other enveloped viruses (PRV, JEV, and DV-II),
EV71 plaque formation remained unaffected by curcumin at all
analyzed concentrations (Fig. 2B) and similar inhibition effect was
observed in IAV and JEV (Fig. 2C).
Curcumin Disrupts the Integrity of Liposomes
Because curcumin had significant effects on HA protein
function in 3 enveloped viruses (2 IAV subtypes and NDV) and
also on the viability of 4 enveloped viruses, we further evaluated
the effects of curcumin pretreatment on the integrity of the viral
envelope using liposomes, a simple lipid structure that mimics the
viral envelope. This was performed using a commercially available
liposome-based transfection reagent and a sulforhodamine B
(SRB)-loaded liposome. In transfection-based system, the trans-
fection efficiency and reporter gene (green fluorescence protein;
GFP) expression level in cells would indicate the function of
liposome that reflects the integrity of liposome structure under
curcumin treatment. As shown in Fig. 3A, incubation of the
liposome/DNA mixture with curcumin (30 mM) markedly de-
creased the overall transfection efficiency and reduced the GFP
signal in transfected cells compared with the DMSO solvent-
control cells. Consistent results were observed in fluorescent SRB-
loaded liposomes. We observed minimal fluorescence when the
SRB was encapsulated in the liposomes. However, following
membrane disruption and the subsequent release of SRB from the
liposomes, fluorescence emission (590 nm wavelength) was detect-
able. Liposomes treated with 30 mM curcumin displayed higher
levels of SRB fluorescence than DMSO-treated liposomes, in-
dicating that curcumin induces leakage of the fluorescent dye
(Fig. 3B). We observed a higher level of SRB leakage from the
liposomes treated with 60 mM curcumin than from those treated
with 30 mm curcumin.
Liposome, as a simpler membrane structure, was used to mimic
envelop structure (Fig. 3A, and B). We then further conducted
Figure 1. Treatment of curcumin reduces infectivity of enveloped viruses. (A) 4 HA units of Newcastle disease viruses (NDV) were incubated
with 2-fold serially diluted curcumin or DMSO (vehicle control) and the hemagglutination inhibitory activity of curcumin was tested by incubation
with chicken RBC at room temperature for 30 minutes. (B) time-of-drug addition test: 10 mM of curcumin or DMSO (as solvent control) was included
into culture medium at various time points of Japanese encephalitis virus (JEV) or Dengue virus (DV-II) infection (200 pfu), for instance: (1) full time
treatment: curcumin was added to vero cells at 8-hour prior to infection and included throughout the time of infection, (2) co-treatment: curcumin
mixed with virus in the infection medium was added simultaneously to the cells and left on the cells throughout; (3) after-entry: curcumin was added
to cells at 2 hpi and remained throughout the time of infection. Small-sized plaque of DV-II was indicated by arrowhead. Consistent results were
observed from at least three independent experiments.
doi:10.1371/journal.pone.0062482.g001
Inhibition of Enveloped Viruses by Curcumin
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e62482
influenza virus competition test to evaluate if the SRB-loaded
liposomes is an adequate model to represent the viral envelope
during curcumin treatment. Presumably if liposome and viral
envelop are similar in terms of lipid structure, then addition of
virus particles was supposed to compete the effect of curcumin on
liposomes. We added 2 doses of influenza virus particles
(2000 PFU and 10 000 PFU) to curcumin and SRB-loaded
liposomes, and then detected fluorescence after 1 h incubation.
The liposomes treated with curcumin alone displayed highest SRB
fluorescence. Addition of influenza virus reduced the curcumin-
induced SRB leakage (Fig. 3C), with higher doses of IAV more
potently reducing the effects of curcumin on SRB leakage.
Curcumin’s Effects on SRB Leakage are Size-dependent
In previous plaque reduction assays, curcumin exerted signif-
icant antiviral effects at subcytotoxic concentrations, with a selec-
tive index of 92.5 [10]. Viral envelopes are derived from cell
membranes; therefore, in this study, we investigated the mechan-
isms by which curcumin selectively disrupts lipid bilayers in
different organelles. The diameter of the influenza virus (80–
100 nm) is approximately 100-fold smaller than that of the
mammalian cell (10 mm). We, thus, investigated the influence of
the sizes of particles on curcumin’s effects. We treated similar
number of SRB-containing liposome particles of 3 different
diameters (300, 220, and 120 nm) with curcumin and evaluated
the leakage of fluorescence. As shown in Fig. 4A, when normalized
with the fluorescence unit in the DMSO control (by subtraction),
we detected the lowest and highest levels of SRB leakage in
liposomes 300 nm and 120 nm in diameter, respectively. This
indicated that curcumin exerts more potent effects on liposomes
with smaller diameters.
Figure 2. Pre-treatment of curcumin strongly inhibited enveloped viruses, but does not affect plaque formation of enterovirus 71
(EV 71). (A) 2,000 pfu of Pseudorabies virus (PRV), Japanese encephalitis virus (JEV), and Dengue virus serotype II (DVII) were pre-treated with 30 mM
of curcumin for one hour and remaining viral infectivity was measured by standard plaque assay. To count plaque numbers, after one hour
incubation, the mixture of virus and drug was further diluted into 1021, 1022, 1023 with medium without serum followed by standard plaque assay.
White spots indicate viral plaques. (B–C) To measure the effect of curcumin, 2,000 pfu of EV71, JEV, and influenza virus, strain PR8 were pre-treated
with a serial dilutions of curcumin (30, 20, 10, 5, 1, 0.5, 0.1 mM to 0 mM) for one hour and the plaque formation ability was measured by standard
plaque assay. Plaque formation ability of EV71 as not inhibited by curcumin, whereas infectivity of influenza viruses was strongly affected (B). Pre-
treatment of curcumin inhibit plaque formation of JEV and Influenza to a similar extent, whereas EV71 remained unaffected (C). The results from Fig.
2C were plotted based on three independent experiments.
doi:10.1371/journal.pone.0062482.g002
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Plaque Formation of Enveloped Viruses with Different
Sizes is Influenced by Curcumin
Envelope structure of viruses is much more complicated than
liposome. The size dependent effect was then tested with viruses
with various sizes. Our previous data has indicated that curcumin
inhibited plaque formation in JEV and the influenza virus (similar
size) to similar extents, with a minimal concentration for complete
inhibition of 3 mM for JEV and 4 mM for influenza (Fig.2B). We
further comparatively compared the effect of curcumin on other
three enveloped viruses including the influenza virus (H1N1
subtype, PR8 strain), PRV, and vaccinia virus. The virions of
influenza virus and PRV are spherical with diameters of
approximately 80 nm to 120 nm, and 150 nm to 200 nm,
respectively. Vaccinia virus, a large DNA virus, is brick-shaped
Figure 3. Curcumin affects the DNA transfection and structure of liposomes. The effect of curcumin on membrane structure was tested in
two systems, commercial liposome-based transfection reagent (A) and Sulforhodamine B (SRB)-loaded liposome (B and C). (A) Curcumin was
incubated with the mixture of eGFP plasmid (Clontech) and Cellfectin (Invitrogen) at room temperature for 40 min before added to the cell
monolayer. At 24-hour post transfection, the transfection efficiency and the intensity of GFP in individual cells were recorded by fluorescent
microscopy (upper panel) and flow cytometry analysis (lower panel). The images were taken under the same setting. (B) SRB-Liposomes were
incubated with various concentrations of curcumin (30 mM, 60 mM), or DMSO (the solvent control) at room temperature for one hour followed by
detection of SRB fluorescence (C) SRB-Liposome was incubated with two different doses of PR8 influenza viruses (2,000 and 10,000 pfu) and curcumin
(60 mM), or DMSO at room temperature for one hour. The leakage of SRB fluorescence was detected by SpectraMax M2e Microplate Reader
(Molecular Devices, Inc., California, United States) at excitation wavelength of 490 nm. The results from Fig. 3B and 3C were plotted based on three
independent experiments.
doi:10.1371/journal.pone.0062482.g003
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and approximately 220 nm to 450 (length)6140 nm to 260 nm
(width)6140 nm to 260 nm (height) in size [25]. Consistently,
curcumin abrogated plaque formation in the influenza virus and
PRV at concentrations $30 mmM. However, at concentrations
ranging from 0.93 mM to 3.75 mM, curcumin treatment exerted
more potent inhibitory effects on influenza virus infectivity than on
PRV infectivity. The curcumin concentration required to reduce
plaque formation by 50% relative to the control (EC50) was
1.15 mM for influenza and 4.61 mM for PRV (Fig. 5B). In-
terestingly, this size dependent effect was more apparent when
comparing the inhibitory effects of curcumin on the influenza virus
with those on the vaccinia virus. As shown in Fig. 4B, curcumin
inhibited the infectivity of the vaccinia virus, an enveloped virus.
However, none of the analyzed curcumin concentrations were
able to fully abrogate vaccinia virus infectivity: the highest
curcumin concentration (60 mM) reduced vaccinia viral plaque
formation to 30% of that in the control experiment. This
concentration was substantially higher than that required for
100% inhibition of JEV and influenza (Figs. 2B and 4B). This
results supports our hypothesis that the requirement for a higher
curcumin concentration to inhibit the infectivity of viral particles
with larger diameters.
Figure 4. Effect of curcumin on liposomes and viruses with different sizes. (A) Three different diameters of SRB-Liposome i.e. 300 nm,
220 nm, 120 nm were incubated with curcumin (60 mM), DMSO (the solvent control), or 15 mM n-octylglucoside (n-OG), a detergent serving as
positive control, at room temperature for one hour. The leakage of SRB fluorescence was detected by SpectraMax M2e Microplate Reader (Molecular
Devices, Inc., California, United States) at excitation wavelength of 490 nm. (B) Effects of curcumin on plaque formation of enveloped viruses with
different sizes. 2,000 pfu of influenza virus (strain PR8) and two DNA viruses, i.e. pseudorabies virus (PRV) and vaccinia viruses (VAC) were pre-treated
with 30 mM of curcumin for one hour. The plaque formation ability was measured by standard plaque assay and plotted as a percentage of the
untreated controls. Dash lines indicate reduction of plaque formation by 50% relative to the control group. Data are presented as mean values 6
standard deviation (SD) from three independent experiments.
doi:10.1371/journal.pone.0062482.g004
Inhibition of Enveloped Viruses by Curcumin
PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e62482
Curcumin-induced Inhibition of Viral Plaque Formation is
Irreversible
Curcumin might inhibit viral infectivity by disrupting mem-
brane integrity or by interfering with membrane protein(s)
function. This study evaluated the efficiency of curcumin’s viral
inhibitory effects and also the reversibility of these effects. In
plaque reduction assays, incubation of the influenza virus with
curcumin (30 mM) for 1 h fully abrogated influenza virus
infectivity (Fig. 2). We then conducted a time course treatment
to determine the time required for plaque reduction. Results
indicated that dramatic decrease of plaque formation was
observed after virus was exposed to curcumin for 5 min; however
a minimal curcumin treatment time of 40 min is required to
completely abrogate plaque formation (Fig. 5A). To evaluate
whether curcumin-induced loss of virus infectivity can be restored,
after pretreatment of curcumin, we diluted the virus-curcumin
mixture to subinhibitory doses of curcumin. As shown in Fig. 4B,
the minimal concentration of curcumin required for complete
inhibition of plaque formation of IAV was ,4 mM. If this effect is
reversible, after 1 h curcumin treatment, subsequent dilutions of
the virus-curcumin mixture to concentrations less than 4 mM
should restore infectivity to certain extents. Results showed that
curcumin treatment, followed by serial dilutions to final concen-
trations of 6 mM, 3 mM, and 1.5 mM, did not reverse the effects of
Figure 5. Effect of curcumin on inhibition of viral plaque formation and infectivity is irreversible. A time course treatment was
conducted to determine the time required for plaque reduction (A). Influenza virus (50 pfu) was mixed with curcumin (30 mM) or DMSO (solvent
control). At different periods of times, i.e. 0, 5, 10, 20, 40, 60 min of incubation, the virus-test drug mixtures were added to cells followed by standard
plaque assay. To evaluate whether curcumin-induced inhibition of viral plaque formation can be restored, one hour after curcumin (30 mM)
treatment, the influenza virus (2000 pfu of PR8) and curcumin mixture was subsequently diluted to final concentrations of curcumin at 6 mM, 3 mM,
and 1.5 mM, followed by standard plaque assay (B). To test whether the curcumin-induced loss of virus infectivity is irreversible, 50 pfu of PR8 viruses
were incubated with 30 mM of curcumin or DMSO in a total volume of 500 ml infectious medium. One hour after incubation, inoculums were injected
into the allantoic sac of 4 embryonated hen’s eggs. Treated eggs were incubated in 37uC incubator for 18 hours, the yield of virus progeny was
determined by HA test (C). Consistent results were observed from at least three independent experiments.
doi:10.1371/journal.pone.0062482.g005
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curcumin, as indicated by the lack of plaque formation (Fig. 5B).
However, dilutions of the virus-solvent control (DMSO) mixture
restored the marginal inhibitory effects of DMSO. We then used
the embryonic chicken egg, a potent amplification vessel for the
influenza virus, to investigate whether curcumin treatment
irreversibility inhibited the influenza virus. Viruses pre-treated
with curcumin (for one hour) were unable to amplify in embryonic
eggs. However, eggs innoculated with a high dose (5000 PFU) of
PR8 treated with DMSO produced 25.5 HA units and 29.75 HA
units of viral progeny at 18 h and 24 h after infection, respectively
(Table 1 and Fig. 5C). These results indicated that the inhibitory
effects of curcumin on influenza virus infectivity are irreversible.
Discussion
This study presents several novel findings. To our knowledge, it
is the first to show that curcumin generally inhibits enveloped virus
infectivity. In addition to inhibiting HA activity, a novel mech-
anism was investigated; as evidenced in the liposome-based assay
systems, we proposed that the integrity of membrane structure,
e.g., viral envelope, could be affected by curcumin treatment. As
for the four enveloped viruses analysed in the current study, the
EC50 of curcumin on inhibition of plaque formation for larger
viruses is greater than that for smaller viruses.
Previous studies reported that curcumin associates with
membranes [26,27]. The hydrophobic properties of membranes
favor the intercalation of curcumin into the lipid bilayer, such as in
cellular membranes, where phenolic rings of curcumin are
essential for interaction with hydrogen-bonding sites. Several
studies also identified curcumin as a membrane-disturbing agent.
Curcumin treatment induced alterations in membranous proper-
ties, including morphological changes, and increased permeability
and fluidity. The interactions between the cell membranes and
curcumin might have caused these effects [26,28]. Jaruga et al.
observed that treatment of erythrocytes with .100 mM curcumin
concentrations induced changes in the integrity of their cell
membranes [26,27]. Similarly, at a high treatment concentration
(5 mM), curcumin increased lactate dehydrogenase (LDH) leakage
in rat hepatocytes (25%) compared with the LDH leakage
observed in untreated cells (15%) [29]. Research using a rat
thymocyte model further showed that curcumin is able to
penetrate the cytoplasm and accumulate in membranous struc-
tures of intracellular organelles and the nuclear membrane. In
addition to inducing morphological changes, curcumin treatment
decreased mitochondrial membrane potentials [28]. In other
studies, curcumin influenced the function of several proteins, such
as epidermal growth factor receptor [30] and P-glycoprotein [31].
These results suggested that additional to curcumin’s effects on
membrane structures, interactions between the phenolic groups of
curcumin and hydrogen bonding sites in the cellular membranes
could influence membrane activities or membrane protein
function.
In our previous study, curcumin effectively interfered with the
HA activity of the influenza virus [10]. In this study, HA activity
was inhibited significantly in NDV treated with curcumin
concentrations higher than 30 mM. The hemagglutinin-neuramin-
idase (HN) protein is responsible for the HA activity of NDV.
Since the HN protein sequence and conformation are dissimilar
from those of the HA protein of the influenza virus, inhibition of
HA function in both viruses after curcumin treatment suggested
that the HI effects might result from different mechanisms, or from
a general disruptive effect on the viral envelope. Following the
treatment of several enveloped viruses and one nonenveloped
virus, EV71 (Piconaviridae) with curcumin, we observed that the
effects of curcumin on inhibition of viral plaque formation are
specific to enveloped viruses: the infectivity of EV71 remained
unaffected by curcumin treatment. As the 7 enveloped viruses,
including influenza A virus (H1 and H6 subtypes), pseudorabies
virus, 2 flaviviruses (JEV and Dengue virus), vaccinia virus, and
NDV, are classified into 5 families, it suggested that curcumin
exerts a general inhibitory effect on viruses with an envelope
structure. Given that pretreatment of the viruses with curcumin
irreversibly abrogated plaque formation and HA activity, it
indicated that curcumin could serve as a virucidal agent for
enveloped viruses.
In this study, the concentration of curcumin required to inhibit
viral HA activity (30 mM) is lower than that reported in our
previous study [10], and those reported by other research groups
as disruptive to erythrocyte membranes [26,27]. In HI assays, we
observed hemolysis at curcumin concentrations higher than
500 mM. Pretreatment of RBC with 30 mM curcumin had no
effects on the HA activity of influenza viruses, indicating that the
erythrocyte membrane remains intact at curcumin concentrations
effective for HA inhibition. At concentrations lower than 30 mM,
we observed insignificant cellular toxic effects. However, EC50
required for inhibition of influenza virus was approximately
0.47 mM (with a selective index, CC50/EC50, of 92.5) [10]. These
observations indicated that, despite viral envelopes and cellular
membranes being composed of a phospholipid bilayer, curcumin
(30 mM) selectively inhibits the infectivity of virus particles by
disrupting the function of viral enveloped proteins, such as the HA
protein of the influenza virus and the HN protein of the NDV.
Cell viability, however, remains unaffected by curcumin treat-
ment. Several factors might contribute to curcumin’s disrupting
effects on different viruses and cells, such as the complexities of
surface protein compositions and the sizes of viral particles.
Numerous surface proteins attach to cellular membranes, whereas
few proteins anchor to the surface of viral particles: Three
envelope proteins (HA, NA, and M2) on the influenza virus, two
envelope proteins (HN and F) on NDV, and two proteins (E and
M) on flaviviruses. Considering the essential roles of each of these
Table 1. Virus yields in embryonic eggs infected with influenza virus pre-treated with curcumin.
Curcumin (+) Curcumin (2)
Yield of virus progeny: HA titer (2n*) Yield of virus progeny: HA titer (2n*)
Virus used 18 hpi 24 hpi 18 hpi 24 hpi
50 pfu 0.00 0.00 0.00 8.2561.71
5000 pfu 0.00 0.00 5.560.58 9.7561.26
*The values of HA titer represent the mean 6 S.E.M. for four independent experiments.
doi:10.1371/journal.pone.0062482.t001
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viral proteins in viral infection, it is likely that interruption of the
function of any viral surface protein by direct interaction with
curcumin, or as a sequential effect resulting from viral envelope
disturbance by curcumin, would have a more significant effect on
virus infectivity than on the cell. In different viruses, 30 mM
curcumin fully abrogated influenza A virus and JEV infectivity
(Fig. 2B), but had minimal inhibitory effects on vaccinia virus
infectivity (Fig. 4B). In general, compared with DNA viruses, RNA
viruses have a smaller-sized genome, encoding fewer proteins and
a simple envelope structure. Among the 4 viruses used for
comparative analysis, both the influenza A virus and JEV are
RNA viruses, with viral particles approximately 50 nm to 100 nm,
and contain 2 or 3 envelope proteins. In contrast, the vaccinia viral
particle is considerably much larger, 220 nm to 450 nm
(length)6140 nm to 260 nm (width)6140 nm to 260 nm (height),
with a more complex structure [32]. It is possible that interference
of the envelope proteins has minimal detrimental effects on
vaccinia virus replication, or that other proteins with similar
functions can compensate for the loss of this activity. Similarly, this
can explain curcumin’s selective inhibitory effects on viruses: the
constitution of surface proteins on cell membrane is much more
complicated than viral envelope, and the average diameter of a cell
ranges from 10 mm to 50 mm; approximately at least 100-fold
larger than that of influenza virus. At identical treatment
concentrations, curcumin would, therefore, exert more potent
effects on small virus particles than on cells.
Previous studies described the inhibitory effects of curcumin on
several enveloped viruses (such as HIV, influenza A virus, herpes
simplex virus, hepatitis B virus) [7,8,9,10,13] and on one
nonenveloped virus, coxsackievirus B3 [6]. In this study, the
infectivity of EV71, which is classified into the same genus as
coxsackievirus B3 (Picornaviridae Enterovirus), remained unaffected
by curcumin treatment. Different experimental designs could have
caused these inconsistent findings. Assay systems (plaque reduction
and HI) of this study evaluated the effects of curcumin on virus
particles and did not consider its effects on cells. However, the
study by Si et al. investigated the cellular effects of curcumin,
observing the suppression of coxsackievirus B3 replication through
dysregulation of the UPS [6]. These different observations indicate
that curcumin inhibits viral infection through multiple mechan-
isms.
Accumulating evidence suggests the potential use of curcumin
as an antiviral drug; however, the mechanisms underlying its
broad spectrum biological effects have yet to be fully elucidated.
Our findings indicate that curcumin has potential anti-viral
activity for a variety of enveloped viruses analyzed in this study
because of its membrane-disturbing (or membrane protein
modification) properties. This novel finding implies that when
evaluating the mechanisms of curcumin-induced antiviral activity
based on the time-of-drug addition experiment, misinterpretation
of the observations is possible. A typical experimental design for
investigation of curcumin’s antiviral activity is the addition of
curcumin to a cell culture medium prior to and/or during the
course of infection [6,13]. In the presence of curcumin, the
effective viral load would decrease significantly during viral
absorption (prior to viral entry). For example, simultaneous
addition of the influenza virus and curcumin to a cell culture
reduced the virus yield to ,5% of that in the control, and viruses
pre-exposed to curcumin prior to infecting MDCK cells markedly
inhibited plaque formation. The initial reduction in the effective
viral load would, thus, contribute to the reductions in virus yields.
The investigation of selected cellular signaling proteins involved in
curcumin-dependent antiviral activity could then be misleading
because reductions in viral replication or yield might not be
exclusively through cellular effects, also resulting from the effects of
curcumin on virus particles during the early stage of infection. An
appropriate experimental design for investigating the effects of
curcumin on enveloped viruses should avoid simultaneous in-
cubation of the test viruses with curcumin during viral absorption
or pre-treatment of virus with curcumin. Curcumin could,
however, be included in the cell culture: (I) before infection but
removed upon viral absorption (i.e., treatment of the cells with
curcumin) to evaluate the establishment of antiviral status in
response to curcumin treatment; and (II) after fusion of the cell
membranes with the viral envelope, or at selected time points after
viral entry, to determine the effects of curcumin on viral
replication procedures and to evaluate the contribution of cellular
machinery during viral infection.
Supporting Information
Figure S1 Cytotoxicity test of curcumin. Vero cells grown
in 96-well (for MTT test) or 24-well (for cell survival analysis)
plates for 16 hours were washed with PBS and were treated with
DMSO (control) or curcumin at indicated concentrations at 37uC,
5% CO2 for 24 hours. Proliferation of cells was then measured by
the standard MTT test (MTT obtained from Sigma-Aldrich) (A),
or directly by the total cell counts (B). (A) For MTT test, cells were
washed with PBS and were then treated with 100 microliter of
MTT solution (0.5 mg/ml) for one hour. Subsequently, the blue
crystals were solublized with 0.04 N HCl in absolute isopropanol
and the intensity is measured colorimetrically at 570 nm. (B) Cell
survival rate was estimated by the ratio of living cells/total cell
counts after stained with 0.4% trypan blue. The cytotoxicity was
estimated by comparison of the cell survival rate of curcumin-
treated cells with that of mock-treated (0 mM). The mock-
treatment control was arbitrary set as 100%. The results were
plotted based on three independent experiments.
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